OB/GYN and Women's Health - Global Oncology Academy

Episodes 17-32 of 77

Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Advances in Women's Health
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
- Ann Klopp, M.D., Ph.D.
Rewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
Rewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
Project Oncology®
Rewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
- Kathleen Moore, MD, MS
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Project Oncology®
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
- Kathleen Moore, MD, MS, FASCO
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Project Oncology®
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
- Kathleen Moore, MD, MS
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
Project Oncology®
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care
- Charles Turck, PharmD, BCPS, BCCCP
- Hope S. Rugo, MD, FASCO
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Project Oncology®
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
Project Oncology®
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
- Komal Jhaveri, MD, FACP
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Project Oncology®
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
- Brian Slomovitz, MD
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Project Oncology®
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
- Brian Slomovitz, MD
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
On the Frontlines of Metastatic Breast Cancer
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
- Marlene Mimi Maeusli, PhD.
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
On the Frontlines of Metastatic Breast Cancer
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
- Ryan Quigley
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer

2/5